The year 2025 presented numerous advances in rheumatology and related inflammatory and autoimmune disorders ranging from several new groundbreaking FDA approvals/indications, drug developments, game-changing guidelines and practices that will impact patient care for rheumatic diseases.

The European Respiratory Society (ERS) and European Alliance of Associations for Rheumatology (EULAR) have published clinical practice guidelines for the evaluation and management of connective tissue diseases (CTD) associated interstitial lung disease (ILD) in two simultaneous publications in

Rheumatologists typically manage systemic autoimmune rheumatic diseases and associated interstitial lung disease with immunosuppressants. However, evidence increasingly supports also the use of antifibrotic agents in this setting.

Dr. Jack Cush reviews the news, journal reports and important associations in rheumatology from the past week on RheumNow.com.

Juvenile dermatomyositis (JDM) is typically recognized for its striking skin rashes, vasculopathy, and muscle inflammation. Less visible, but equally significant, is lung involvement. Interstitial lung disease (ILD) is increasingly acknowledged as a critical driver of morbidity and

Children with juvenile idiopathic inflammatory myositis (JIIM) are at risk of developing lung disease, notably interstitial lung disease (ILD). ILD can be asymptomatic initially, progressing silently to irreversible lung damage, which underscores the importance of early detection

When I see patients with RA-associated ILD, I’m often asked: “Are the lungs and joints really connected?” The answer is yes, and the connection extends further back than some may realize. While RA is defined by inflammation of the joints, extra-articular complications of the lung are well

The American Journal of Managed Care has reviewed the approach to patients with interstitial lung disease (ILD); a significant cause of morbidity and mortality in those with systemic autoimmune rheumatic diseases (SARDs), including rheumatoid arthritis (RA), systemic sclerosis (SSc), and

Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Pool therapy, Fibrosis, NSIE's and what's best for knee OA. 

Idiopathic Interstitial Pneumonia with Autoimmune Features - or IPAF - describes patients with interstitial pneumonia with autoimmune features, but they don’t meet a diagnosis of a CTD.

Several cohort studies conducted in Asia, Europe and the Americas have evaluated the clinical significance of antineutrophil cytoplasmic antibodies (ANCA) when detected in patients with interstitial lung disease (ILD) as well as the types of ILD encountered in patients with microscopic